Body mass index and breast cancer survival: A Mendelian randomisation analysis

Background: There is increasing evidence that elevated body mass index (BMI) is associated with reduced survival for women with breast cancer. However, the underlying reasons remain unclear. We conducted a Mendelian randomization analysis to investigate a possible causal role of BMI in survival from breast cancer. Methods: We used individual-level data from six large breast cancer case-cohorts including a total of 36210 individuals (2475 events) of European ancestry. We created a BMI genetic risk score (GRS) based on genotypes at 94 known BMI-associated genetic variants. Association between the BMI genetic score and breast cancer survival was analysed by Cox regression for each study separately. Study-specific hazard ratios were pooled using fixed-effect meta-analysis. Results: BMI genetic score was found to be associated with reduced breast cancerspecific survival for estrogen receptor (ER)-positive cases [hazard ratio (HR)¼1.11, per one-unit increment of GRS, 95% confidence interval (CI) 1.01–1.22, P¼0.03). We observed no association for ER-negative cases (HR¼1.00, per one-unit increment of GRS, 95% CI 0.89–1.13, P¼0.95). Conclusions: Our findings suggest a causal effect of increased BMI on reduced breast cancer survival for ER-positive breast cancer. There is no evidence of a causal effect of higher BMI on survival for ER-negative breast cancer cases.